Cookies help us to develop our website and to improve its content and availability. Some cookies are necessary to ensure that the website functions properly. You can accept all cookies or just the necessary cookies. To change settings, click Cookie Settings. You can access the settings later from the Cookie practices page of the tukija.fi website.
Select an option below to determine which cookies to allow. When you are ready, click Save and exit. The website works even if you only agree to necessary cookies. There might be some differences, however. You can also change the settings later through our pages. Read more about the cookies on this tukija.fi website.
The necessary cookies are automatically stored on your browser when you use our web service. These cookies are used to ensure that the valvira.fi web service functions as intended.
Web analytics tool (Google Analytics) helps us to understand how our customers use the valvira.fi web service and from where they access the website.
We use the Siteimprove service to monitor the availability of the website, the functioning of links and the visibility of the website on search engines.
nullThe use of the CTIS system will be extended from 31.1.2023
The use of the CTIS system will be extended from 31.1.2023
11.1.2023 11:23
/
News
The transition period according to the EU regulation on clinical drug trials (536/2014) ends for new research plans. From 31 January 2023 all new clinical drug trials must be submitted for evaluation by the authorities via the European Medicines Agency's CTIS system.
